Venus Remedies Ltd (VENUSREM) — shareholding pattern, promoter holding, financials and share price
About Venus Remedies Ltd (VENUSREM)
Venus Remedies Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as VENUSREM and on the BSE under scrip code 526953. Its ISIN is INE411B01019.
Incorporated in 1989, Venus Remedies Ltd is a research based pharmaceutical company and an injectable manufacturer [1]
Venus Remedies Ltd is a pharmaceutical company specializing in injectables and intravenous supplies with global reach through WHO-GMP certified facilities.
In recent years, the company has had notable product launches, including the innovative anti-cancer drug 'Docetaxel' in Europe and 'Cytomib,' a treatment for blood cancer.
Listed peers in Pharmaceuticals: Kwality Pharmaceuticals Ltd, Sai Parenterals Ltd, Indoco Remedies Ltd, Beta Drugs Ltd, Ind-Swift Laboratories Ltd, NGL Fine Chem Ltd.
Valuation & Returns
10 Jul 2026At ₹1,717 a share on 10 Jul 2026, Venus Remedies Ltd (VENUSREM) was valued at a price-to-earnings ratio of 22.32x against an industry P/E of 36.41x and a price-to-book of 4.09x on a book value of ₹419.65 per share as of Mar 2025. Solomo computes return on equity of 18.33% and return on capital employed of 23.85% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 22.32x
- Industry P/E
- 36.41x
- P/B
- 4.09x
- EPS (TTM)
- ₹76.91
- Book value / share
- ₹419.65
- ROE
- 18.33%
- ROCE
- 23.85%
- ROA
- 14.36%
- Debt / equity
- 0x
- Dividend yield
- 0.58%
- EBITDA margin
- 20.77%
- 52-week range
- ₹423.7 – ₹2,043.15
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Venus Remedies Ltd (VENUSREM) reported revenue of ₹770 crore, net profit of ₹103 crore and earnings per share of ₹76.9. That compares with revenue of ₹640 crore and net profit of ₹45 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹259 crore and net profit ₹48 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 597 | 552 | 596 | 640 | 770 |
| Net profit (₹ cr) | 41 | 27 | 28 | 45 | 103 |
| EPS (₹) | 30.46 | 19.88 | 21.31 | 33.9 | 76.9 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 5.27% | 14.83% | 3.50% | 7.72% |
| Profit growth | 52.14% | - | 2.38% | 59.04% |
| Stock price CAGR | 35% | 31% | 85% | 240% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 41.76% of Venus Remedies Ltd (VENUSREM) (unchanged from the previous quarter), foreign institutional investors (FII) hold 2.92% and domestic institutional investors (DII) hold 0.89%. Market capitalisation was ₹2,295 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2001.
Largest disclosed public shareholders in Jun 2026: LLP 2.13%, TIKRI PARTNERS LLP 1.97%, HUF 1.94%, RAJNI TARUN JAIN 1.42%, ACADIAN EMERGING MARKETS MICRO-CAP EQUITY MASTER FUND 1.1%, NISARG AJAYKUMAR VAKHARIA 1.05%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 41.76% | - | 2.92% | 0.89% | 58.24% |
| Mar 2026 | 41.76% | - | 2.8% | 1.2% | 58.24% |
| Dec 2025 | 41.76% | - | 2.26% | 1.03% | 58.24% |
| Sep 2025 | 41.76% | - | 1.86% | 0.75% | 58.24% |
| Jun 2025 | 41.76% | - | 2.24% | 0.11% | 58.24% |
| Mar 2025 | 41.76% | - | 1.34% | - | 58.24% |
| Dec 2024 | 41.76% | - | 1.11% | - | 58.24% |
| Sep 2024 | 41.76% | - | 1.18% | 0.15% | 58.24% |